On Wednesday, Shares of Red Hat Inc (NYSE:RHT), gained 0.73% to $73.25.
Red Hat, declared two new service offerings from Red Hat Training and Certification focused on improving IT professionals’ skills and expertise in Red Hat-distributed OpenStack clouds.
Red Hat has assisted hundreds of organizations develop the necessary skills and knowledge to install, configure, manage, and build OpenStack clouds. Recently, there are thousands of Red Hat Certified System Administrators (RHCSA) in Red Hat OpenStack throughout more than 40 countries worldwide, and Red Hat anticipates that number to grow.
The two new service offerings comprise an IT engineer-level OpenStack certification, Red Hat Certified Engineer (RHCE) in Red Hat OpenStack, and accompanying exam, Red Hat Certified Engineer in Red Hat OpenStack exam (EX310) in addition to an IT engineer-level course, Red Hat OpenStack Administration III (CL310).
Red Hat, Inc. provides open source software solutions to enterprise customers worldwide. It develops and offers operating system, virtualization, middleware, storage, and cloud technologies.
Shares of XenoPort, Inc. (NASDAQ:XNPT), declined -0.73% to $4.10, during its last trading session.
XenoPort, declared positive preliminary top-line results from its Phase 2 clinical trial of XP23829 as a potential treatment for moderate-to-severe chronic plaque-type psoriasis. XP23829 met its primary endpoint in both 800 mg once daily and 400 mg twice daily doses, demonstrating statistically noteworthy improvements in percent change from baseline to week 12 in Psoriasis Area and Severity Index (PASI) score. XP23829 is a patented prodrug of monomethyl fumarate (MMF) in a novel oral formulation that was designed to potentially offer physicians and patients an effective, better tolerated and easier to use therapeutic option to presently available fumarate products.
XenoPort, Inc., a biopharmaceutical company, focuses on developing and commercializing a portfolio of product candidates for the treatment of neurological and other disorders. It offers HORIZANT (gabapentin enacarbil) extended-release tablets for the treatment of moderate-to-severe primary restless legs syndrome in adults and for the administration of postherpetic neuralgia in adults.
At the end of Wednesday’s trade, Shares of Royal Bank of Canada (NYSE:RY), lost - 0.87% to $53.73.
Over half of Canadians (57 per cent) are entrepreneurs at heart and have thought of owning their own business, according to a recent RBC Small Business survey. While one-third (36 per cent) of Canadians who have thought of owning a business have actually started one, 84 per cent of those who have not started a business say they would rather work for themselves than for someone else.
Royal Bank of Canada, together with its auxiliaries, operates as a diversified financial service company worldwide. The company operates through five segments: Personal & Commercial Banking, Wealth Administration, Insurance, Investor & Treasury Services, and Capital Markets.
Finally, Kimberly Clark Corp (NYSE:KMB), ended its last trade with 0.02% gain, and closed at $107.86.
Kimberly-Clark Corporation, declared the availability of the new Poise Impressa Bladder Supports – an innovative over-the-counter internal solution designed to assist stop leaks before they happen.
Safe, comfortable and effective, Poise Impressa Bladder Supports give women an option that assists them stop worrying about leaks so they can experience a renewed sense of freedom and the confidence to enjoy an active, fulfilling life.
Kimberly-Clark Corporation, together with its auxiliaries, manufactures and markets personal care, consumer tissue, and K-C professional products worldwide. It operates through three segments: Personal Care, Consumer Tissue, and K-C Professional.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
